Bluewillow
Ann Arbor, US · 1 known investors
Find your way into Bluewillow
155 people in our graph share verified history with the Bluewillow team — schools, employers, funds. One of them is your warm intro.
Prashant Shahunlockedknows George Arida · together at University of Illinois Urbana-Champaign (overlapped)
×7knows the team · via University of Chicago
×3knows the team · via University of Illinois Urbana-Champaign
knows the team · via Harrington Discovery Institute at University Hospitals
BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.
Founders & leadership
CC
Chad CostleyinPresident and Chief Executive Officer
GA
George AridainChief Financial and Operating OfficerGeorge Arida is Chief Financial and Operating Officer of BlueWillow Biologics, a clinical-stage biotech firm developing an intranasal vaccine delivery platform. He has held roles as an investor, board member, and operator in biotechnology ventures spanning small molecule therapeutics, biologics, and vaccine development, and serves as fund manager at the Harrington Discovery Institute.
JS
Jakub SimonChief Medical Officer
Investors · 1
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $299.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $215.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $297.3K |
| Environmental Protection Agency (EPA) | Phase II | 2005 | $225K |
| Environmental Protection Agency (EPA) | Phase II | 2005 | $224.7K |
| Environmental Protection Agency (EPA) | Phase I | 2004 | $69.9K |
| Environmental Protection Agency (EPA) | Phase I | 2004 | $69.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Bluewillow do?
- BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.
- Who are Bluewillow's investors?
- Bluewillow's investors include Michigan Capital Network.
- Where is Bluewillow headquartered?
- Bluewillow is headquartered in Ann Arbor, US.